GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks Rutherford, NJ, Dec. 03, 2024 (GLOBE NEWSWIRE) --...

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS Diabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) --...

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet...